SUPPLEMENTARY MATERIAL

		Months of DAPT*	In-stent/in-segment thrombosis			
			(events/total number of patients)		Geographical	Month of
Study, year	Design Intervention		Early (0 – 30 days)	Late (>30 days)	mismatch addressed?	follow- up
DEBIUT Registry [59], 2008	Observational DIOR I DEB in MB and SB + BMS in MB	3	0/20	0/20	Yes	4
LOCAL TAX [21], 2009	Randomised BMS + Genie DEB BMS Taxus DES	6	0/67 0/67 1/67	0/67 0/67 0/67	Yes	6
PEPCAD I [37], 2010	Observational Sequent Please DEB SeQuent Please DEB + BMS	1 3	0/82 1/32	0/82 1/32	No	12
PICCOLETO [48], 2010	Randomised DIOR DEB DIOR DEB + BMS Taxus Liberté DES	1 3 12	0/28 N/A 0/29	0/28 N/A 0/29	No	9
SeQuent Please World Wide Registry [39], 2010	Observational SeQuent Please DEB SeQuent Please DEB + BMS	1	Not reported spec lesions	cifically for de novo	Yes	9
Sgueglia <i>et al.</i> [61], 2011	Observational BMS + "various" DEB	3	0/14		No	8
PEPCAD V [60], 2011	Observational SeQuent Please DEB in MB and SB + BMS in MB	3	0/28	2/28	Yes	9
PERfECT [24], 2011	Randomised SeQuent Please DEB + EPC EPC alone	3	0/62	0/62	Yes	6
PEPCAD IV DM [76], 2011	Randomised SeQuent Please DEB + BMS vs. Taxus Liberté DES	3	0/58 0/58 Not reported whether early or late: 0/45		Yes	9
De Novo Pilot Study [32], 2011	Randomised Moxy DEB + BMS BMS + Moxy DEB	3	0/13 0/13	0/13 0/13	Yes	6
BELLO [49], 2012	Randomised IN.PACT Falcon DEB IN.PACT Falcon DEB + BMS Taxus Liberté DES	1 3	0/90	0/90	Yes	6
DEAR [77], 2012	Observational DIOR II DEB + BMS "various" BMS "various" DES	3	0/92 0/92 Not reported whether early or late: 2/91 1/96 4/129		Yes	12
DEBIUT [62], 2012	Randomised DEB in MB and SB + BMS in MB BMS in MB and POBA in SB DES in MB and POBA in SB	3 3 12	0/40 0/37 1/40	0/40 0/37 0/40	Yes	12
DEB-AMI [50], 2012	Randomised DIOR II DEB + BMS BMS Taxus DES	12	2/50 0/51 0/49	0/50 0/51 0/49	Yes	6
PEPCAD CTO [67], 2012	Observational SeQuent Please DEB + BMS Taxus DES	6 12	0/48 0/48	0/48	Yes	12

Liistro et	Randomised 51.1.		0.150	0/50	v	
al.[31],	Elutax DEB + BMS vs.	3	0/59	0/59	Yes	9
2013	Xience DES	12	1/66	0/66		
INDICOR [33],	Randomised		-/			
2013	SeQuent Please DEB + BMS	3	2/49	1/49	No	12
	VS.			- 4		
	BMS + SeQuent Please DEB	3	1/48	0/48		
PEGASUS [26],	<u>Observational</u>					
2013	IN.PACT Falcon DEB + EPC	3	0/40	0/40	Yes	9
	Stent					
Valentines II	<u>Observational</u>					
[10],	DIOR II DEB	3	0/102	0/102	No	7.5
2013						
Calé et al. [40],	Observational					
2013	SeQuent Please	3	0/74	0/74	No	12
Basavarajaiah	Observational					
et al. [68],	IN.PACT Falcon DEB +	12	0/20	0/20	No	13
2013	"various" DES					
Costopoulos et	Observational					
al. [69],	IN.PACT Falcon/Pantera	1-12	0/69	0/69	No	26
2013	Lux DEB ± "various" DES					
	"Various" DES	12	1/93	0/93		
SeQuent Please	<u>Observational</u>					
Small Vessel	SeQuent Please DEB	1-12	0/420	0/420	No	9
'PCB only'	SeQuent Please DEB + BMS		0/27	0/27		
Registry [35],						
2014						
Schulz et al.	<u>Observational</u>					
[63],	SeQuent Please DEB or	1	0/38	0/38	Yes	4
2014	In.Pact Falcon DEB					
BABILON [64],	Randomised					
2014	SeQuent Please DEB in MB	3	0/52	1/52	Yes	24
	and SB + BMS in MB					
	Xience V DES in MB	12	1/56	0/56		
Basavarajaiah	Observational					
et al. [70],	IN.PACT Falcon DEB +/-DES	1-12	0/79	0/79	No	15
2014						
OCTOPUS [28],	Randomised					
2014	BMS + SeQuent Please DEB	12	Not reported		Yes	6
	Xience V DES					
PAPPA [71],	<u>Observational</u>					
2014	Pantera LUX DEB	12	1/100	0/98	No	12
DELUX Registry	Obsrvational					
[46] , 2014	Pantera Lux DEB	3	1/105	0/104	Yes	12
Kleber et al.	<u>Observational</u>					
[52],	SeQuent Please	1	0/56 (?)	0/56	Not relevant**	4
2015	DEB/IN.PACT Falcon DEB					
BIOLUX-I study	<u>Observational</u>					
[65] , 2015	DES in MB + DEB in SB	6	0/34	0/34 (1 possible)		12
IN-PACT CORO	BMS	3	0/10	0/10	Yes	12
[23] , 2015	IN.PACT Falcon DEB + BMS		0/10	0/10		
	BMS + IN.PACT Falcon DEB		0/10	0/10		
Zurakowski et	Randomised					
al. [27], 2015	SeQuent Please DEB + BMS	12	4/102	1/102	Yes	9
	Coroflex™Please DES	12	1/100	2/100		
Spanish DIOR	Observational					
Registry [47],	DIOR I/II DEB	1	0/97	0/97	Yes	12
2015	DIOR I/II DEB + BMS		0/7	1/7		
Shin et al. [54],	Observational					
2015	SeQuent please DEB	1.5	0/45	0/45	No	12
	DES	12	0/22	0/22		
DEB-AMI	Observational					
"Fourth arm"	DIOR II	?	0/40	0/40	Yes	6
[72],						
[72], 2015						
	Observational					

[73] , 2015	SeQuent Please DEB	Not reported	0/89	0/89	Not relevant**	1
The Leipzig Registry [42], 2016	Observational SeQuent Please DEB	3	0/76	Not reported	No	1
Her et al. [53], 2016	Observational SeQuent Please DEB POBA	1.5	Not reported		Not relevant**	9
Benezet <i>et al.</i> [41], 2016	Observational SeQuent Please DEB SeQuent Please + BMS	1 6-12	0/39 0/14	0/39 0/14	No	36
Ann et al. [55] 2016	Observational SeQuent Please DEB	Not reported	0/27	0/27	Not relevant**	12

* Minimum recommendations of DAPT treatment

** By design no stent implanted

See Table 1 and 3 in the main article for abbreviations.

Figure S1. Flowchart of the literature selection process

PubMed

•Date: 14/4-2016 •Search strategy

•(((de novo lesion OR naive vessel OR native vessel OR coronary vessel OR coronary arter*))
AND Paclitaxel AND balloon*)

Filters: English languagePublication years: 10 years

•Hits: 707

•Included: 43 Studies

•Follow up: 3 (BELLO 2 year, PEPCAD I 36

months, PERfECT 5 year)

•Substudy: 5 (IVUS Study, Clever et al, Otto et al., Zuhdi et al., Sinaga et al., Ong et al.)

Embase

•Date: 14/4 - 2016

• Search Strategy
•(((de novo lesion OR naive vessel OR native

vessel OR coronary vessel OR coronary arter*))
AND Paclitaxel AND balloon*)

• Publication years: 2006 and forward

•Hits: 815

•Included: 39 Studies

• Follow up: 3 (BELLO 2 year, PEPCAD I 36 months,

PERfECT 5 year)

•2 Substudies (IVUS Study, Clever et al., Sinaga et

al.)







Total litterature search

- •Thirty-four records were duplicates and thus removed
- Reasons for exclusion were typically that the articles focused on in-stent restenosis and that the studies compared different DESs instead of DEBs.
- •In total: 48 different studies

Search by hand

- Reference lists and reviews were searced by hand.
- Hits: 4
- IN.PACT-CORO, Valentines II Trial, Sgueglia *et al.*, PEPCAD-BIF



Final studies

- •Included: 52
- Follow-up: 3 (BELLO 2 year, PEPCAD I 36 months, PERfECT 5 year)
- •Substudy: 5 (IVUS Study, Clever *et al*, Otto *et al.*, Zuhdi *et al.*, Sinaga *et al.*, Ong *et al.*)